Market Overview

UPDATE: Jefferies Upgrades Sequenom to Buy on Reimbursement Coverage Outlook

Related SQNM
Events for the Week of Sept. 8-12
Sequenom Labs Reports Expanded Int'l Noninvasive Prenatal Testing Service with VisibiliT Test

Jefferies raised its rating on Sequenom (NASDAQ: SQNM) from Hold to Buy with a reiterated $7 price target.

Jefferies said, "We are upgrading shares of SQNM to Buy (from Hold) based on results from a proprietary survey we conducted of US commercial payors representing some 44 million lives, which indicated SQNM is experiencing meaningful traction obtaining reimbursement coverage for its T21 LDT test at average rates that we find more than acceptable. Our $7 price target (>90% upside) is unchanged."

Sequenom closed at $3.60 on Friday.

Latest Ratings for SQNM

DateFirmActionFromTo
Jun 2014William BlairUpgradesMarket PerformOutperform
Jan 2014Piper JaffrayDowngradesOverweightNeutral
Nov 2013Maxim GroupReiteratesBuy

View More Analyst Ratings for SQNM
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (SQNM)

Around the Web, We're Loving...

Get Benzinga's Newsletters